Literature DB >> 35222570

A novel survival algorithm in COVID-19 intensive care patients: the classification and regression tree (CRT) method.

Sevinç Dağıstanlı1, Süleyman Sönmez2, Murat Ünsel3, Emre Bozdağ1, Ali Kocataş1, Merve Boşat4, Eray Yurtseven5, Zeynep Çalışkan6, Mehmet Güven Günver5.   

Abstract

BACKGROUND/AIM: The present study aimed to create a decision tree for the identification of clinical, laboratory and radiological data of individuals with COVID-19 diagnosis or suspicion of Covid-19 in the Intensive Care Units of a Training and Research Hospital of the Ministry of Health on the European side of the city of Istanbul.
MATERIALS AND METHODS: The present study, which had a retrospective and sectional design, covered all the 97 patients treated with Covid-19 diagnosis or suspicion of COVID-19 in the intensive care unit between 12 March and 30 April 2020. In all cases who had symptoms admitted to the COVID-19 clinic, nasal swab samples were taken and thoracic CT was performed when considered necessary by the physician, radiological findings were interpreted, clinical and laboratory data were included to create the decision tree.
RESULTS: A total of 61 (21 women, 40 men) of the cases included in the study died, and 36 were discharged with a cure from the intensive care process. By using the decision tree algorithm created in this study, dead cases will be predicted at a rate of 95%, and those who survive will be predicted at a rate of 81%. The overall accuracy rate of the model was found at 90%.
CONCLUSIONS: There were no differences in terms of gender between dead and live patients. Those who died were older, had lower MON, MPV, and had higher D-Dimer values than those who survived.
© 2021 Dağıstanlı S et al.

Entities:  

Keywords:  COVID-19 intensive care patients; CRT method; Survival algorithm

Mesh:

Year:  2021        PMID: 35222570      PMCID: PMC8843255          DOI: 10.4314/ahs.v21i3.16

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


Introduction

Corona Virus Disease 2019 (COVID-19) was first reported in the city of Wuhan in China in December 2019. Here, the newly identified human-coronavirus was named temporarily as 2019-nCoV, and then, with a common consensus, renamed as Severe Acute Respiratory Syndrome-Related Coronavirus “SARS-CoV-2” 1. SARS-CoV-2 spread quickly around the world from Wuhan, China, where it was first announced, and was declared as pandemia by the WHO on March 11, 2020. Again, on the same day, it was announced by the Ministry of Health that the first case was detected in Turkey, and on March 17, 2020, the first death occurred due to SARS-CoV-2. As of May 12, 2020, it was announced as current figures that the total number of cases was 141.475, there were 3894 total deaths, the number of patients in intensive care was 1045, and 576 people were intubated. With the spread of SARS-CoV-2 among countries, thanks to the strong healthcare service structure of the Ministry of Health of the Republic of Turkey, and by seeing the processes experienced by other countries, necessary precautions, measures and emergency action plans were performed quickly. In this process, the kits that were required for PCR tests were brought to the country, all private, foundation, university and public hospitals that had 3rd Level Intensive Care Units, and at least two of the chest diseases, infectious diseases and internal expertise services, were converted into pandemia hospitals and provided free services for all citizens in the framework of SARS-CoV-2. CT devices were quickly included in use for SARS-CoV-2 scans when PCR test is insufficient or incomplete, and were quickly reported by radiologists who were specialized in the field. In the light of the algorithms that were updated by the Ministry of Health and according to CT and clinical findings, it was ensured that patients were quarantined in services or in intensive care units or at homes to prevent rapid spread. Many people with COVID-19 infection face the disease mildly, and have flu-like symptoms like fever and cough, others may be asymptomatic, and some patients may have Acute Respiratory Distress Syndrome (ARDS). The patients who develop ARDS may require respiratory support, and for this reason, the need for intensive care may appear. Initial reports published show that approximately 5% of proven COVID-19 infections are associated with serious disease that require intensive care 2. In light of these reports, according to 2018 data, with 38,908 intensive care beds capacity, considering the intensive care and intubation requirement that might increase, all surgeries -except for emergency surgeries were cancelled especially in Istanbul, the most populous city of the country with a population of 15 million 519 thousand 267 people, and surgery rooms and other related areas in many other cities have been converted into intensive care units. For this reason, the present study aimed to create a decision tree for the identification of clinical, laboratory and radiological data of individuals with COVID-19 diagnosis or suspicion of Covid-19 in the Intensive Care Units of a Training and Research Hospital of the Ministry of Health on the European side of the city of Istanbul.

Material and Methods

The present study, which had retrospective and sectional design, covered all the patients treated with Covid-19 diagnosis or suspicion of Covid-19 in the intensive care of Kanuni Sultan Suleyman Research and Training Hospital between 12 March and 30 April, 2020. Firstly, the approval for the study was obtained from the Chief Physician; application for permission was made to the Ministry of Health, and the approval was obtained from the Ethics Committee of Science, Social and Non-Interventional Health Sciences Research at Istanbul Yeni Yuzyıl University as a result of the meeting on 11.05.2020 with the number 2020/04-05. The number of the beds in the hospital where the study was conducted is 648. It also has a total of 40 intensive care beds with ventilator devices. In addition, there are 32 beds with ventilator device in the 3rd Stage and 8 beds ventilator device in the 2nd Stage for adults. There are a total of 4 CT devices in our hospital, and 3 CT Devices were gradually allocated only for Covid-19-suspicious cases, depending on patient density. No sampling method was used in the study, and a total of 97 cases were included. In all cases who had symptoms (fever, cough, shortness of breath, etc.) admitted to the Covid-19 clinic, nasal swab samples were taken and thoracic CT was performed when considered necessary by the physician, radiological findings were interpreted (atypical, typical-mild, typical-moderate-severe), and clinical and laboratory data were included to create the decision tree. The following were considered in the interpretation of the CT results. Atypical: Unilateral ground glass density or consolidated areas. Typical (mild): (Lung parenchyma involvement 1–25%): Bilateral peripheral-weighted patchy focal multiple ground glass density areas. Typical (moderate-severe) (Lung parenchyma involvement 25–100%): Bilateral, widespread and consolidated multiple ground glass densities in peripheral-weighted patchy form combining at places in the upper and middle lobes of both lungs. The CTs were performed in Somatom Definition AS+, Siemens Healthineers, Germany CT Device. The patients were in supine position. 16-dedector 0.75mm section thickness tube voltage = 120 kVp, automatic tube current modulation (30 - 70 mAs), pitch = 0.99 - 1.22 mm, matrix = 512 × 512, slice thickness = 10 mm, field of view = 350 mm × 350 mm. A decision tree was created in which the laboratory data and imaging results of the cases recorded during the hospital admission step, alanine aminotransferase (ALT), Albumin, aspartate aminotransferase (AST), C-reactive protein (CRP), Ferritin, basophils (BASO), eosinophils (EO), hematocrit (HTC), hemoglobin (HGB), lymphocytes (LYM), monocyte (MON), mean platelet volume (MPV), Neutrophils (NEU), platelet (PLT), red blood cell (RBC), white blood cell (WBC), creatine kinase (CK), lactate dehydrogenase (LDH), procalcitonin (Procal), troponin I (Trop_I), D_dimer laboratory data were taken as independent variables, and survival was taken as dependent variable. The Classification and Regression Tree (CRT) algorithm was applied to these variables 3. The result of the Computerized Tomography (CT) was used as the influence variable (2) in the decision tree 4.

Results

A total of 97 cases who were diagnosed with Covid-19 with PCR testing or CT findings and who were referred to intensive care at Kanuni Sultan Suleyman Training and Research Hospital were evaluated in this study. A total of 61 of the cases included in the study died, and 36 were discharged with cure from the intensive care process (Table-1).
Table 1

Survival status of Covid-19 intensive care patients by gender

p=0.913GenderTotal
FemaleMale
SurvivalDead214061
Live122436
Total336497
Survival status of Covid-19 intensive care patients by gender The baseline (before the intensive care) characteristics of the relevant cases are as follows. As seen in Table 2;
Table 2

Baseline Characteristics of Covid-19 intensive care patients

Group Statistics
SurvivalNMeanStd. DeviationStd. Error Meanp
AgeDead6168.3811.601.490.0000
Live3653.6918.893.15
ALTDead6134.5724.503.140.3076
Live3629.6120.233.37
AlbuminDead6137.7239.545.060.6519
Live3634.725.480.91
ASTDead6151.0535.844.590.2163
Live3641.2540.116.69
CRPDead61138.48102.5313.130.3443
Live35220.20660.23111.60
FerritinDead58871.36893.98117.390.4805
Live34737.81834.96143.19
BASO (10^9/L)Dead610.040.130.020.3133
Live360.020.020.00
EO (10^9/ L)Dead600.020.070.010.5113
Live360.030.070.01
Htc (%)Dead6136.316.980.890.4272
Live3635.127.311.22
HGB (g/dL)Dead6112.162.440.310.5742
Live3611.872.550.43
LYM (10^9/L)Dead611.332.450.310.7372
Live361.190.620.10
MON (10^9/L)Dead610.480.280.040.0366
Live360.610.360.06
MPV (fL)Dead6010.271.220.160.0243
Live3510.800.810.14
NEU (10^9/L)Dead61117.77864.63110.710.4439
Live366.753.860.64
PLT (10^9/L)Dead61206,295.08100,749.0912,899.600.1815
Live36233,527.7888,058.2614,676.38
RBC (10^9/L)Dead6111.7958.097.440.4373
Live364.220.910.15
WBCDead6112,178.7629,619.033,792.330.3892
Live367,871.964,418.98736.50
CKDead47416.66924.77134.890.2794
Live33233.00338.0758.85
LDHDead47436.98241.5335.230.2807
Live29378.65201.7537.46
ProcalDead5913.9287.3611.370.4096
Live361.826.211.04
Trop_IDead490.070.130.020.3159
Live300.210.920.17
D_ dimerDead539.8611.871.630.0082
Live333.746.681.16
There were no differences in terms of gender between dead and live patients. Those who died were older than those who survived. Those who died had lower MON values than those who survived. Those who died had lower MPV values than those who survived. Those who died had higher D_Dimer value than those who survived. Baseline Characteristics of Covid-19 intensive care patients The Survival - CT Cross Table of the cases transferred to intensive care are given below (Table-3).
Table 3

Survival - CT comparison of the Covid-19 intensive care patients

p=0.406CT_New GroupingTotal
Typical (Mild)Typical (Moderate- Severe)Atypical
SurvivalDead6421361
Live722736
Total13642097
Survival - CT comparison of the Covid-19 intensive care patients A Decision Tree was created in which baseline laboratory values, age, gender and laboratory data were included as the independent variables, and survival status as dependent variable, and the analyses were conducted by using the CT results as the influence variable applying the CRT algorithm. The influence variable is the intermediary variable, which is not included in the structure of the tree, but is used in calculations for the creation of such trees 3, 4. The predicted/observed matrix of the decision tree is below (Table 4).
Table 4

Decision tree success table of Covid-19 intensive care patients

ObservedPredicted
DeadSurvivalAccuracy Percentage
Dead58395.1%
Survival72980.6%
Overall Percentage67.0%33.0% 89.7%
Decision tree success table of Covid-19 intensive care patients By using the de c ision tree algorithm created in this study (fig-1), dead cases will be predicted at a rate of 95%, and those who survive will be predicted at a rate of 81%. The overall accuracy rate of the model was found as 90%.
Figure 1

CRT Decision Tree

CRT Decision Tree

Discussion

COVID-19 emerged before us as a threat for the preparations of all countries and biosecurity conditions. Clinical data, laboratory findings, and radiological imaging results provide clinicians with critical information, which must be examined carefully when a new infectious disease appears. Among current diagnostic methods for COVID-19, there are detection of the virus with genomic techniques by using Polymerase Chain Reaction (PCR)-based methods or deep sequence method. The fact that viral genome is not adequate in the amplifiable sample collection area in these detection methods, viral replication does not have a time window, incorrect sample collection are among the reasons, which can limit the usability of the quantitative PCR (qPCR)-based analysis5–7. Such limitations can cause false negative diagnoses, and cause such patients spread the infection rapidly, prevent the efforts spent to avoid the spread of the virus, and produce serious consequences. Because of these reasons, laboratory tests and imaging methods are important in identifying fake PCR-negative patients. In the present study, the relation between mortality in intensive care patients and epidemiological, laboratory and imaging was investigated. As mentioned in previous studies, it was found in our study that age has a big effect on mortality. As the age increases, so do mortality rates. The mortality rates increased when the age increased above 52 in the decision tree mentioned above. The procalcitonin value is of great importance in these patients, especially in significant laboratory findings of inflammation. In a study conducted retrospectively on 191 patients in China, it was shown that Covid-19-related in-hospital mortality rates increased with increased age 8. In a multi-center study conducted on 150 patient records in China, significant differences were found in terms of age among the survivors and those who died9. It can be speculated that our results coincide with the results of the studies conducted on age. Patients with procalcitonin values below 0.055 ng/ml who were included in the study had 100% survival rates. The mortality rate was measured to be 82.9% in people with procalcitonin level above 0.055 ng/ml. In a compilation study 10, it was emphasized that high serum procalcitonin and ferritin values showed poor prognostic factors. In a previous study 11, the data obtained in terms of Covid-19 and laboratory parameters were published in the form of a letter to the editor, and it was reported that procalcitonin values were increased in patients admitted to the Intensive Care Unit. These two studies show parallel results with the present study of ours. In patients who had procalcitonin values above 0.055 ng/ml, the CK value, which is one of the important enzymes in our body, was an important parameter; and mortality was measured to be 87.7% in patients with CK >63.5 compared to 61.5% in patients with CK <63.5. In a single-center study conducted on 138 hospitalized patients admitted to intensive care unit in China, higher levels of D-dimer and creatine kinase were found in laboratory findings 12. In the present study, similarly, it was found that the creatine kinase and D-dimer values were high in intensive care patients. In the final step of the decision tree, the acute phase reactant ferritin values are important. The mortality rate was 0% in patients with <422.65 ferritin value and CK<63.5, it was 100% in patients with >422.65. In addition, while the mortality rate was 93.6% in patients with ferritin value <1376.5 and CK>63.5, it was 60% in patients with 1376.5 ferritin value. In a meta-analysis study 13, it was emphasized that serum ferritin levels were a powerful differential parameter in the severity of the disease. In our study, the ferritin levels appeared before us as a strong differential parameter in intensive care patients. In a study conducted on 201 Covid-19 patients in China, it was shown that the high serum ferritin levels were associated with ARDS development; however, these levels did not tend to have a relation with survival. However, in our study, it was found that there was a relation between ferritin levels and survival in our patients 14. In a previous study 8 conducted with 191 patients, similar to our study, higher serum ferritin levels and higher mortality rates were associated in the single-variable analysis, and they did not provide a multivariate analysis. In addition, according to baseline statistics, the D_Dimer values of dead individuals were higher than the surviving individuals. In a multi-center study conducted with 1099 Covid-19 patients, it was found that D-Dimer values increased in 46.4% of patients, and that these values was higher at significant levels in severe Covid-19 cases 15. In a previous study, it was concluded that the D-dimer levels were higher in patients who needed intensive care support (Median D-dimer 2.4 mg / L for ICU, 0.5 mg / L for non-ICU) 16.

Conclusion

In the present study, it was found that age is an important factor in patients treated with Covid-19 diagnosis or suspicion of it in intensive care. It was observed that the levels of procalcitonin, which is an indicator of inflammation in the decision tree, and acute phase reactant ferritin values were important mortality parameters. Although the limitation of the present study was the number of patients, studies conducted on Covid-19 patients who need intensive care are extremely limited. The biggest problem in pandemics is that intensive care units become unable to serve in this process despite the rate of spread of the disease. For this reason, the subject of the present study that was investigated will provide us information about the progress of the disease in intensive care and before, and the contribution of our study to the literature is undeniable. In this respect, it is recommended to conduct more comprehensive studies with larger groups for intensive care patients with the data obtained here.
  16 in total

1.  Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender.

Authors:  Thomas P Cappola; Manya R Harsch; Mariell Jessup; William T Abraham; James B Young; Susan Petersen-Stejskal; Ted Plappert; Martin St John Sutton
Journal:  J Card Fail       Date:  2006-04       Impact factor: 5.712

2.  Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial.

Authors:  A T C Chan; P M L Teo; R K Ngan; T W Leung; W H Lau; B Zee; S F Leung; F Y Cheung; W Yeo; H H Yiu; K H Yu; K W Chiu; D T Chan; T Mok; K T Yuen; F Mo; M Lai; W H Kwan; P Choi; P J Johnson
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

3.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

4.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

5.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Authors:  Qiurong Ruan; Kun Yang; Wenxia Wang; Lingyu Jiang; Jianxin Song
Journal:  Intensive Care Med       Date:  2020-03-03       Impact factor: 17.440

6.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.

Authors:  Victor M Corman; Olfert Landt; Marco Kaiser; Richard Molenkamp; Adam Meijer; Daniel Kw Chu; Tobias Bleicker; Sebastian Brünink; Julia Schneider; Marie Luisa Schmidt; Daphne Gjc Mulders; Bart L Haagmans; Bas van der Veer; Sharon van den Brink; Lisa Wijsman; Gabriel Goderski; Jean-Louis Romette; Joanna Ellis; Maria Zambon; Malik Peiris; Herman Goossens; Chantal Reusken; Marion Pg Koopmans; Christian Drosten
Journal:  Euro Surveill       Date:  2020-01

7.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

8.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

9.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

10.  Hematological findings and complications of COVID-19.

Authors:  Evangelos Terpos; Ioannis Ntanasis-Stathopoulos; Ismail Elalamy; Efstathios Kastritis; Theodoros N Sergentanis; Marianna Politou; Theodora Psaltopoulou; Grigoris Gerotziafas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2020-05-23       Impact factor: 13.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.